OIS Co-Chair Emmett T. Cunningham Jr., MD, PhD, MPH laid out hopeful – and cautionary – signs facing the ophthalmology industry as he kicked off last week’s OIS@AAO with his comprehensive Year in Review presentation.
Speaking before more than 900 people gathered at the Hyatt Regency Chicago, Cunningham reviewed the industry’s successes with the FDA, including the approvals secured by big players – Shire and Allergan – as well as smaller companies like Avedro and ReVision.
He also laid out the clinical trials to watch in the coming months, a list that headlined Aerie Pharmaceuticals and Ophthotech.
For those interested in obtaining a copy of Cunningham’s expanded Year in Review presentation, which will include slides not presented at the conference, keep an eye out in upcoming Eye on Innovation Newsletters. We’ll present an easy opportunity for you to download the presentation.
Emmett T. Cunningham Jr., MD, PhD, MPH
Dr. Cunningham, currently a Partner, joined Clarus in 2006 with more than 20 years of experience in the biomedical and biopharmaceutical sectors.